Rubicon Research Limited IPO

Established in 1999, Rubicon Research Limited is a pharmaceutical company dedicated to the development, manufacturing, and commercialization of differentiated drug formulations. As of June 30, 2025, the company boasts a robust portfolio that includes 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products which have received approval from the US FDA.

Don't have a Navia account? Sign up

This extensive portfolio features 66 commercialized products. Rubicon Research Limited holds a significant presence in the US generic pharmaceutical market, which was valued at USD 2,455.7 million. The company's own contribution to this market was approximately USD 195 million in Fiscal Year 2024.

How do I apply for the Rubicon Research IPO?

You can apply for the Rubicon Research IPO using any supported UPI app by following two steps:

• Enter your bid on rocket
• Accept UPI mandate on your phone

On acceptance of the mandate, the bid amount will get blocked in your bank account.